First Time Loading...

Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 60.96 USD -3.97% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

EXACT Sciences Corp. is a cancer screening and diagnostics company. [ Read More ]

The intrinsic value of one EXAS stock under the Base Case scenario is 62.33 USD. Compared to the current market price of 60.96 USD, Exact Sciences Corp is Undervalued by 2%.

Key Points:
EXAS Intrinsic Value
Base Case
62.33 USD
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Exact Sciences Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EXAS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Exact Sciences Corp

Provide an overview of the primary business activities
of Exact Sciences Corp.

What unique competitive advantages
does Exact Sciences Corp hold over its rivals?

What risks and challenges
does Exact Sciences Corp face in the near future?

Has there been any significant insider trading activity
in Exact Sciences Corp recently?

Summarize the latest earnings call
of Exact Sciences Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Exact Sciences Corp.

Provide P/S
for Exact Sciences Corp.

Provide P/E
for Exact Sciences Corp.

Provide P/OCF
for Exact Sciences Corp.

Provide P/FCFE
for Exact Sciences Corp.

Provide P/B
for Exact Sciences Corp.

Provide EV/S
for Exact Sciences Corp.

Provide EV/GP
for Exact Sciences Corp.

Provide EV/EBITDA
for Exact Sciences Corp.

Provide EV/EBIT
for Exact Sciences Corp.

Provide EV/OCF
for Exact Sciences Corp.

Provide EV/FCFF
for Exact Sciences Corp.

Provide EV/IC
for Exact Sciences Corp.

Show me price targets
for Exact Sciences Corp made by professional analysts.

What are the Revenue projections
for Exact Sciences Corp?

How accurate were the past Revenue estimates
for Exact Sciences Corp?

What are the Net Income projections
for Exact Sciences Corp?

How accurate were the past Net Income estimates
for Exact Sciences Corp?

What are the EPS projections
for Exact Sciences Corp?

How accurate were the past EPS estimates
for Exact Sciences Corp?

What are the EBIT projections
for Exact Sciences Corp?

How accurate were the past EBIT estimates
for Exact Sciences Corp?

Compare the revenue forecasts
for Exact Sciences Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Exact Sciences Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Exact Sciences Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Exact Sciences Corp compared to its peers.

Compare the P/E ratios
of Exact Sciences Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Exact Sciences Corp with its peers.

Analyze the financial leverage
of Exact Sciences Corp compared to its main competitors.

Show all profitability ratios
for Exact Sciences Corp.

Provide ROE
for Exact Sciences Corp.

Provide ROA
for Exact Sciences Corp.

Provide ROIC
for Exact Sciences Corp.

Provide ROCE
for Exact Sciences Corp.

Provide Gross Margin
for Exact Sciences Corp.

Provide Operating Margin
for Exact Sciences Corp.

Provide Net Margin
for Exact Sciences Corp.

Provide FCF Margin
for Exact Sciences Corp.

Show all solvency ratios
for Exact Sciences Corp.

Provide D/E Ratio
for Exact Sciences Corp.

Provide D/A Ratio
for Exact Sciences Corp.

Provide Interest Coverage Ratio
for Exact Sciences Corp.

Provide Altman Z-Score Ratio
for Exact Sciences Corp.

Provide Quick Ratio
for Exact Sciences Corp.

Provide Current Ratio
for Exact Sciences Corp.

Provide Cash Ratio
for Exact Sciences Corp.

What is the historical Revenue growth
over the last 5 years for Exact Sciences Corp?

What is the historical Net Income growth
over the last 5 years for Exact Sciences Corp?

What is the current Free Cash Flow
of Exact Sciences Corp?

Financials

Balance Sheet Decomposition
Exact Sciences Corp

Current Assets 1.2B
Cash & Short-Term Investments 777.6m
Receivables 203.6m
Other Current Assets 213.1m
Non-Current Assets 5.3B
PP&E 853.4m
Intangibles 4.3B
Other Non-Current Assets 166.1m
Current Liabilities 514.7m
Accounts Payable 78.8m
Accrued Liabilities 371.1m
Other Current Liabilities 64.8m
Non-Current Liabilities 2.8B
Long-Term Debt 2.3B
Other Non-Current Liabilities 489.6m
Efficiency

Earnings Waterfall
Exact Sciences Corp

Revenue
2.5B USD
Cost of Revenue
-654.2m USD
Gross Profit
1.8B USD
Operating Expenses
-2.1B USD
Operating Income
-214.4m USD
Other Expenses
10.2m USD
Net Income
-204.1m USD

Free Cash Flow Analysis
Exact Sciences Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EXAS Profitability Score
Profitability Due Diligence

Exact Sciences Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
34/100
Profitability
Score

Exact Sciences Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

EXAS Solvency Score
Solvency Due Diligence

Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
41/100
Solvency
Score

Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EXAS Price Targets Summary
Exact Sciences Corp

Wall Street analysts forecast EXAS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXAS is 92.47 USD with a low forecast of 66.66 USD and a high forecast of 120.75 USD.

Lowest
Price Target
66.66 USD
9% Upside
Average
Price Target
92.47 USD
52% Upside
Highest
Price Target
120.75 USD
98% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EXAS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EXAS Price
Exact Sciences Corp

1M 1M
-3%
6M 6M
-5%
1Y 1Y
-8%
3Y 3Y
-51%
5Y 5Y
-33%
10Y 10Y
+378%
Annual Price Range
60.96
52w Low
56.27
52w High
99.04
Price Metrics
Average Annual Return -9.36%
Standard Deviation of Annual Returns 36.06%
Max Drawdown -80%
Shares Statistics
Market Capitalization 11.1B USD
Shares Outstanding 181 114 000
Percentage of Shares Shorted 3.52%

EXAS Return Decomposition
Main factors of price return

What is price return decomposition?

EXAS News

Other Videos

Last Important Events
Exact Sciences Corp

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Exact Sciences Corp

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Exact Sciences Corp Logo
Exact Sciences Corp

Country

United States of America

Industry

Biotechnology

Market Cap

11.1B USD

Dividend Yield

0%

Description

EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. The company is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.

Contact

WISCONSIN
Madison
5505 Endeavor Lane
+16082845700.0
https://www.exactsciences.com/

IPO

2001-01-30

Employees

6 420

Officers

Chairman of The Board & CEO
Mr. Kevin T. Conroy
EVP & CFO
Mr. Jeffrey T. Elliott CFA
Executive Vice President of Human Resources
Ms. Sarah Condella
Chief Commercial Officer
Mr. Everett V. Cunningham
Chief Science Officer
Dr. Jorge A. Garces Ph.D.
Chief Information Officer
Mr. Nassar Nizami
Show More
Associate Manager of Investor Relations
Ms. Megan Jones
Chief Compliance Counsel & VP
Mr. Tim Caprez
Senior VP, General Counsel & Secretary
Mr. James Herriott
Head of Sales
Mr. Vic Parker
Show Less

See Also

Discover More
What is the Intrinsic Value of one EXAS stock?

The intrinsic value of one EXAS stock under the Base Case scenario is 62.33 USD.

Is EXAS stock undervalued or overvalued?

Compared to the current market price of 60.96 USD, Exact Sciences Corp is Undervalued by 2%.